BioSpace News Archive

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Clarissa Desjardins, Ph.D., to its Board of Directors

The American Diabetes Association (ADA) today announced a new collaboration with VSP® Vision Care, a VSP Global® company which serves nearly 90 million members as the largest and only national not-for-profit vision benefits provider, to focus on an often overlooked but costly and devastating complication of diabetes: eye disease.

Cerveau Technologies, Inc. today announced that the first healthy volunteer was injected and scanned in the Japan Phase I study of [F18]MK-6240, an investigational imaging agent

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Donald Notman, Chief Financial Officer of Ocular Therapeutix, will give a company presentation on Thursday, November 21st at 8:40 a.m.

VBI Vaccines (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, and Brii Biosciences (“Brii Bio”), a clinical-stage company committed to serving patients’ needs and improving public health in China and around the world, today announced the first patient dosed in a Phase 1b/2a proof-of-concept study of BRII-179 (VBI-2601

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 1:50 p.m. Eastern Time.

Highlights Include: ALS Phase 3 Clinical Trial Fully Enrolled, Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue, Appointment of CFO, Phase 2 in Progressive MS Continues to Enroll Patients

Axonics Modulation Technologies, Inc. announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration for the clinical indications of overactive bladder and urinary retention.

Technavio has announced its latest market research report titled global diabetic neuropathy drugs market 2019-2023

Eagle Pharmaceuticals, Inc. announced that Douglas L. Braunstein is stepping down from the Company’s Board of Directors, effective November 14, 2019.